Clinical trials on modifiers of vascular endothelial growth factor signaling (e.g., bevacizumab and cediranib) in high-grade gliomas revealed early marked reduction in contrast enhancement without significant increase in overall survival [26, 27]. Here, VEGFA is linked to glioma.